Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
Novocure (NASDAQ: NVCR) announced promising results from the 2-THE-TOP phase 2 pilot trial for treating newly diagnosed glioblastoma (GBM) using Tumor Treating Fields (TTFields), pembrolizumab, and temozolomide. Patients in the trial experienced a median progression-free survival of 12.1 months, significantly better than the 7.9 months seen in a matched-control group from the EF-14 trial. Moreover, overall survival was 25.2 months versus 15.9 months for controls. These findings will be presented at WFNOS 2022, with Dr. David Tran leading the discussion.
- Median progression-free survival in 2-THE-TOP was 12.1 months, compared to 7.9 months in the EF-14 control group.
- Overall survival for 2-THE-TOP participants was 25.2 months, versus 15.9 months for controls.
- 40% of patients in 2-THE-TOP achieved partial to complete response.
- None.
Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14
These preliminary results, which are based on a median follow-up time of 16.8 months, compare outcomes for 26 patients in the ongoing 2-THE-TOP trial versus a historical, matched-control group of 26 patients from the TTFields plus temozolomide arm of the phase 3 pivotal EF-14 clinical trial. For patients in the 2-THE-TOP trial, median progression-free survival was 12.1 months, compared with 7.9 months for the matched-control patients in EF-14 (hazard ratio=0.46, p=0.033). Patients in 2-THE-TOP had a median overall survival of 25.2 months, compared with 15.9 months for the matched-control patients in EF-14 (hazard ratio=0.38, p=0.020).
Of the 15 patients in 2-THE-TOP with measurable target lesions, six (
“These data from 2-THE-TOP are exciting and point to the potential benefit of Tumor Treating Fields together with pembrolizumab and temozolomide,” said
In a preclinical study published in the
“We are very encouraged by the data from Dr. Tran’s 2-THE-TOP study, and by the mechanistic insights published by his research group in JCI,” said
Dr. Tran’s oral presentation at WFNOS 2022 is one of three oral presentations at the conference highlighting research on TTFields.
Dr.
Dr.
In addition, 28 posters at WFNOS 2022 will feature research on TTFields.
TTFields is investigational for the treatment of newly diagnosed GBM when used together with pembrolizumab.
About 2-THE-TOP
The 2-THE-TOP trial is an investigator-initiated, phase 2 pilot trial designed to assess the safety and preliminary efficacy of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for the treatment of adult patients with newly diagnosed GBM. Patients enrolled in the trial underwent maximal tumor resection followed by standard chemoradiation. Following the completion of chemoradiation, patients began a course of monthly cycles of adjuvant temozolomide. Treatment with TTFields started at approximately the same time as the first cycle of adjuvant temozolomide. Pembrolizumab was introduced in the second cycle of treatment and subsequent cycles of pembrolizumab were administered every three weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
About EF-14
The EF-14 trial was a randomized, phase 3 pivotal trial which compared, post radiation, TTFields plus temozolomide versus temozolomide alone for the treatment of newly diagnosed GBM. Median progression-free survival, the primary endpoint, was 6.7 months for TTFields plus temozolomide versus 4 months for temozolomide alone. Median overall survival was 20.9 months for TTFields plus temozolomide versus 16 months for temozolomide alone.
About Tumor Treating Fields
Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division. Fundamental scientific research extends across more than two decades and, in all preclinical research to date, TTFields have demonstrated a consistent anti-mitotic effect. TTFields therapy is intended principally for use together with other standard-of-care cancer treatments. There is a growing body of evidence that supports TTFields’ broad applicability with certain other cancer therapies, including radiation therapy, certain chemotherapies and certain immunotherapies. In clinical research and commercial experience to date, TTFields therapy has exhibited no systemic toxicity, with mild to moderate skin irritation being the most common side effect. The TTFields global development program includes a network of preclinical collaborators and a broad range of clinical trials across all phases, including four phase 3 pivotal trials in a variety of tumor types. To date, more than 22,000 patients have been treated with TTFields therapy.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the
Headquartered in Jersey, and with a growing global footprint, Novocure has regional operating centers in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005952/en/
Investors:
investorinfo@novocure.com
610-723-7427
Media:
media@novocure.com
610-723-7428
Source: Novocure
FAQ
What were the results of the NVCR 2-THE-TOP trial?
When will the NVCR 2-THE-TOP trial results be presented?
What is the primary treatment regimen in the NVCR 2-THE-TOP trial?
How many patients were involved in the NVCR 2-THE-TOP trial?